Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer

• Main Authors: Gabrielle P. Dailey (Author), Christopher A. Rabiola (Author), Gangjun Lei (Author), Junping Wei (Author), Xiao-Yi Yang (Author), Tao Wang (Author), Cong-Xiao Liu (Author), Melissa Gajda (Author), Amy C. Hobeika (Author), Amanda Summers (Author), Robert D. Marek (Author), Michael A. Morse (Author), Herbert K. Lyerly (Author), Erika J. Crosby (Author), Zachary C. Hartman (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment inevitably results in therapeutic resistance, whic...